CTOs on the Move

Lupin Pharmaceuticals

www.lupinpharmaceuticals.com

 
Lupin is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD Lupin is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Spacelabs Healthcare

Spacelabs Healthcare is an American manufacturer of medical equipment and is a wholly owned subsidiary of OSI Systems of Hawthorne, California and offers products and services from three divisions: patient monitoring and connectivity, anesthesia delive...

SST Corporation

SST Corporation is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Osteal Therapeutics

Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.

Canderm Pharma

Canderm Pharma, Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.